Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Feb 24, 2026 · 10-K · 55 days after period end · 0001193125-26-065197
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $871.00K | $295.00K |
| Net Income | -$20.33M | -$16.57M | -$24.76M | -$24.78M |
| EPS Diluted | — | — |
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
| — |
| -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Feb 24, 2026 · 55 d after period end
